Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SK life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
Details : Phase 3 clinical trial initiated to evaluate the efficacy and safety of YKP509 (carisbamate) for the treatment of seizures associated with LGS. Carisbamate has also received orphan drug designation from the FDA.
Product Name : YKP509
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
